Clinical Trials

Orano Med, RadioMedix recruit first patients in AlphaMedix phase 1 clinical trial

Orano Med and RadioMedix have recruited first three patients in the AlphaMedix phase 1 clinical trial.

BerGenBio completes recruitment into first stage of phase II breast cancer trial

BerGenBio has completed enrolment of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib (BGB324) in combination with the Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as a potential new treatment regimen for advanced breast cancer.

Lilly’s Taltz yields positive results in phase 3 genital psoriasis trial

Eli Lilly and Company reported that Taltz (ixekizumab) in a phase 3b trial has helped patients with moderate-to-severe genital psoriasis in significantly reducing the impact of their condition on sexual activity.

Lilly’s radiographic axial spondyloarthritis treatment Taltz succeeds in phase 3 study

Eli Lilly announced that Taltz (ixekizumab) has met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (axSpA).

Diurnal Group completes patient enrolment in Chronocort’s trial for congenital adrenal hyperplasia

Diurnal Group has completed patient enrolment in its European pivotal Phase III clinical trial of Chronocort (modified release hydrocortisone) for the treatment of congenital adrenal hyperplasia (CAH) in adults.

Apalutamide delays spread of several prostate cancers in phase 3 trial

A group of investigators have demonstrated in a phase 3 clinical trial that apalutamide, an inhibitor of androgen receptor, delays spread of certain prostate cancers that had become resistant to standard androgen-deprivation therapy.

AstraZeneca’s Brilinta shows benefits for heart attack patients in phase III trial

AstraZeneca’s Brilinta significantly reduced cardiovascular (CV) events and coronary death beyond one year in heart attack survivors with multi-vessel disease in a Phase III trial.

Roche’s Tecentriq/Avastin combo succeeds in phase 3 kidney cancer trial

Roche said that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26% in certain people with advanced kidney cancer in a Phase III study.

Sage Therapeutics’ SAGE-217 shows positive effect in phase 1/2 insomnia trial

Sage Therapeutics’ sleep disorder drug SAGE-217 has yielded positive results from a phase 1/2 trial in healthy adult volunteers using a 5-hour phase advance model of insomnia using polysomnography.